ABSTRACT
Pearl millet (Pennisetum glaucum) is a nutritious and drought-resistant cereal grain that has been traditionally grown in many parts of the world, particularly in arid and semiarid regions. In recent years, there has been growing interest in the potential significance of pearl millet in the management and prevention of diabetes mellitus. This review will discuss some of the prospective benefits and significance of pearl millet for individuals with diabetes mellitus. Pearl millet has a low glycemic index, which means it has a relatively slow and steady impact on blood sugar levels when compared to high-GI foods. This is particularly beneficial for individuals with diabetes as it can help control post-meal blood sugar spikes. It's important to note that while pearl millet can be a valuable addition to the diet of individuals with diabetes, it should be part of a well-balanced diet that is tailored to their specific needs. The overall dietary approach should be coordinated with a healthcare professional or dietitian to ensure that it aligns with the individual's health goals and needs. Additionally, individuals with diabetes should monitor their blood sugar levels and make adjustments to their diet in consultation with a healthcare provider, as the impact of specific foods can vary from person to person. Pearl millet, like any other food, should be consumed in moderation as part of a diversified diet. In conclusion, pearl millet has the potential to be a significant component of a diabetes-friendly diet due to its low glycemic index, high fiber content, nutrient profile, and antioxidant properties. However, it should be part of an overall strategy that includes other healthy eating habits and lifestyle choices to effectively manage and prevent diabetes mellitus.
ABSTRACT
OBJECTIVE: To evaluate the clinico-epidemiological profile of Acinetobacter sepsis in neonates. DESIGN: Retrospective study. SETTING: Level II Neonatal Care Unit. SUBJECTS: 79 neonates with blood culture positive for Acinetobacter. METHODS: Relevant information was collected on a predesigned proforma from the case records and analyzed for clinical and epidemiological characteristics. RESULTS: The incidence of Acinetobacter septicemia was 11.1/1000 live births. Fifty-five babies were hospital born, 24 were outborn. Out of these, 64.6% babies were born at term and 40.5% had a birth weight of 2500 g or more. A cluster of 53 cases was seen between May and September 1995. In cases with early onset sepsis (onset < 7 days of postnatal age), difficulty in breathing (n = 54), chest retraction (n = 35) and refusal to feed (n = 46) were seen more commonly as compared to late onset sepsis (p < 0.05). Complications observed included meningitis, bleeding manifestations and necrotising enterocolitis in three, six and five babies, respectively. The organism was sensitive to ciprofloxacin (96.2%), amikacin (92.4%) and gentamicin (87.3%). A response rate of 52.4% was observed with Ciprofloxacin in babies not responding to cefotaxime and amikacin combination. The overall mortality was 13.9%. CONCLUSION: Nosocomial Acinetobacter sepsis may affect fullterm, appropriate for gestational age babies. Clinical presentation is indistinguishable from Gram negative septicemia. Life threatening complications can also occur. Ciprofloxacin may prove to be useful drug in resistant cases.